Hepatitis C Core-Antigen Testing from Dried Blood Spots.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
06 09 2019
Historique:
received: 04 08 2019
revised: 31 08 2019
accepted: 05 09 2019
entrez: 7 9 2019
pubmed: 7 9 2019
medline: 4 9 2020
Statut: epublish

Résumé

In order to expand hepatitis C virus (HCV) screening, a change in the diagnostic paradigm is warranted to improve accessibility and decrease costs, such as utilizing dried blood spot (DBS) collection. In our study, blood from 68 patients with chronic HCV infection was spotted onto DBS cards and stored at the following temperatures for one week: -80 °C, 4 °C, 21 °C, 37 °C, and alternating 37 °C and 4 °C; to assess whether temperature change during transportation would affect sensitivity. Sample was eluted from the DBS cards and tested for HCV antibodies (HCV-Ab) and HCV core antigen (core-Ag). HCV-Abs were detected from 68/68 DBS samples at -80 °C, 4 °C, 21 °C, and 67/68 at 37 °C and alternating 37 °C and 4 °C. Sensitivity of core-Ag was as follows: 94% (-80 °C), 94% (4 °C), 91% (21 °C), 93% (37 °C), and 93% (37 °C/4 °C). Not only did temperature not greatly affect sensitivity, but sensitivities are higher than previously reported, and support the use of this assay as an alternative to HCV RNA. We then completed a head-to-head comparison (

Identifiants

pubmed: 31489933
pii: v11090830
doi: 10.3390/v11090830
pmc: PMC6784259
pii:
doi:

Substances chimiques

Hepatitis C Antibodies 0
Hepatitis C Antigens 0

Types de publication

Evaluation Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

J Clin Virol. 2014 Nov;61(3):359-64
pubmed: 25264306
J Hepatol. 2014 Nov;61(1 Suppl):S45-57
pubmed: 25086286
J Int AIDS Soc. 2017 Sep 14;20(1):21856
pubmed: 28953324
J Viral Hepat. 2014 May;21 Suppl 1:1-4
pubmed: 24713003
Semin Liver Dis. 2014 Feb;34(1):89-97
pubmed: 24782262
J Mol Diagn. 2018 Sep;20(5):621-627
pubmed: 29959023
J Viral Hepat. 2019 Feb;26(2):236-245
pubmed: 30338887
Expert Rev Mol Diagn. 2017 Dec;17(12):1109-1115
pubmed: 29088981
J Int AIDS Soc. 2017 May 15;20(1):21446
pubmed: 28530032
J Viral Hepat. 2018 Jun;25(6):680-698
pubmed: 29345844
Clin Infect Dis. 2019 Apr 03;:null
pubmed: 30943286
J Hepatol. 2016 Oct;65(1 Suppl):S46-S66
pubmed: 27641988
Am J Med. 2013 Aug;126(8):718-22
pubmed: 23786667
PLoS One. 2014 Mar 06;9(3):e86461
pubmed: 24603442
Int J Drug Policy. 2017 Sep;47:51-60
pubmed: 28683982
Frontline Gastroenterol. 2017 Jul;8(3):221-228
pubmed: 28839912
Clin Infect Dis. 2014 Oct;59(7):976-81
pubmed: 24991025
BMJ Open. 2013 Aug 13;3(8):null
pubmed: 23943776
Ann Gastroenterol. 2015 Apr-Jun;28(2):221-228
pubmed: 25830779
Ann Intern Med. 2016 Sep 6;165(5):345-55
pubmed: 27322622
Front Public Health. 2017 Dec 18;5:348
pubmed: 29326922
J Infect Dis. 2016 Apr 1;213(7):1087-95
pubmed: 26333945
Clin Transl Gastroenterol. 2016 Sep 22;7(9):e193
pubmed: 27657495
Hepatology. 2009 Apr;49(4):1090-7
pubmed: 19263473

Auteurs

Mia J Biondi (MJ)

Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, University of Toronto, Toronto, ON M5G 2C4, Canada. mia.biondi@mail.mcgill.ca.
Viral Hepatitis Care Network (VIRCAN) Study Group, Toronto Centre for Liver Disease, Toronto, ON M5G 2C4 Canada. mia.biondi@mail.mcgill.ca.
Arthur Labatt Family School of Nursing, Western University, London, ON N6A 3K7, Canada. mia.biondi@mail.mcgill.ca.

Marjolein van Tilborg (M)

Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, University of Toronto, Toronto, ON M5G 2C4, Canada. m.vantilborg@erasmusmc.nl.
Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam 3015 GD, The Netherlands. m.vantilborg@erasmusmc.nl.

David Smookler (D)

Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, University of Toronto, Toronto, ON M5G 2C4, Canada. david@vircan.ca.
Viral Hepatitis Care Network (VIRCAN) Study Group, Toronto Centre for Liver Disease, Toronto, ON M5G 2C4 Canada. david@vircan.ca.

Gregory Heymann (G)

Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, University of Toronto, Toronto, ON M5G 2C4, Canada. gregory.heymann@mail.utoronto.ca.

Analiza Aquino (A)

Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada. aaquino@mtsinai.on.ca.

Stephen Perusini (S)

Public Health Ontario Laboratories, Toronto, ON M5G 1M1, Canada. stephen.perusini@oahpp.ca.

Erin Mandel (E)

Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, University of Toronto, Toronto, ON M5G 2C4, Canada. erin.mandel@uhnresearch.ca.
Viral Hepatitis Care Network (VIRCAN) Study Group, Toronto Centre for Liver Disease, Toronto, ON M5G 2C4 Canada. erin.mandel@uhnresearch.ca.

Robert A Kozak (RA)

Department of Microbiology, Sunnybrook Health Sciences, Toronto, ON M4N 3M5, Canada. rob.kozak@sunnybrook.ca.

Vera Cherepanov (V)

Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, University of Toronto, Toronto, ON M5G 2C4, Canada. vera.a.ch@gmail.com.

Matthew Kowgier (M)

Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5T 3M7, Canada. matt.kowgier@gmail.com.

Bettina Hansen (B)

Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, University of Toronto, Toronto, ON M5G 2C4, Canada. bettina.hansen@utoronto.ca.
Viral Hepatitis Care Network (VIRCAN) Study Group, Toronto Centre for Liver Disease, Toronto, ON M5G 2C4 Canada. bettina.hansen@utoronto.ca.

Lee W Goneau (LW)

Public Health Ontario Laboratories, Toronto, ON M5G 1M1, Canada. lee.goneau@gmail.com.

Harry L A Janssen (HLA)

Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, University of Toronto, Toronto, ON M5G 2C4, Canada.
Viral Hepatitis Care Network (VIRCAN) Study Group, Toronto Centre for Liver Disease, Toronto, ON M5G 2C4 Canada.

Tony Mazzulli (T)

Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada. tony.mazzulli@sinaihealthsystem.ca.
Public Health Ontario Laboratories, Toronto, ON M5G 1M1, Canada. tony.mazzulli@sinaihealthsystem.ca.

Gavin Cloherty (G)

Abbott Molecular, Des Plaines, IL 60018, USA. gavin.cloherty@abbott.com.

Robert J de Knegt (RJ)

Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam 3015 GD, The Netherlands. r.deknegt@erasmusmc.nl.

Jordan J Feld (JJ)

Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, University of Toronto, Toronto, ON M5G 2C4, Canada. jordan.feld@uhn.ca.
Viral Hepatitis Care Network (VIRCAN) Study Group, Toronto Centre for Liver Disease, Toronto, ON M5G 2C4 Canada. jordan.feld@uhn.ca.
Institute of Medical Sciences, University of Toronto, Toronto, ON M5S 1A8, Canada. jordan.feld@uhn.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH